Parasite glycolytic enzyme

Parasite glycolytic enzymes are a class of metabolic enzymes that mediate the stepwise conversion of glucose or other hexoses to pyruvate, generating ATP and metabolic intermediates essential for growth and survival. These enzymes are critical in the biology of many parasites, including protozoa (e.g., Plasmodium, Trypanosoma, Leishmania) and helminths (e.g., Schistosoma, Fasciola), where glycolysis is often the principal source of ATP, especially in oxygen-limited environments or specific life stages[1][2][3][4][5][6][8]. Many parasites have evolved isoforms or unique localizations (such as glycosomal compartmentalization in trypanosomatids), which differ structurally and mechanistically from host enzymes, presenting opportunities for selective drug targeting[2][6][7]. Several glycolytic enzymes have been validated as drug or vaccine targets, with existing therapeutics such as Melarsoprol, pentamidine, Clorsulon, and trivalent antimonials demonstrating proof-of-concept in the clinic[2][4][6]. However, therapeutic development is challenged by the high structural similarity to host enzymes and potential toxicity from off-target effects[4][6]. Mutations in target enzymes can confer drug resistance, and careful selection of isoforms or allosteric sites unique to parasites is an emerging focus in rational drug development[1][2][3][8]. Note: The supplied target name ("Parasite glycolytic enzymes") is a non-canonical, overly broad, and plural term that refers to a *family* of enzymes rather than a specific molecular entity; in most drug discovery or clinical contexts, individual glycolytic enzymes (e.g., "Phosphofructokinase from Plasmodium falciparum") should be used as targets instead[1][2][3][4][7][8].

Other names

parasitic glycolytic enzymesglycolytic pathway enzymes (parasites)glycosomal glycolytic enzymes (for kinetoplastids/trypanosomatids)

Inhibition of glycolytic enzymes leading to parasite ATP depletion and cell death[2][4][6][8] Disruption of metabolic pathways unique to the parasite (e.g., glycosome targeting in trypanosomatids[2]) Metabolic poisoning (antimonials/Clorsulon mechanisms[4]) Indirect sensitization to other pathway inhibitors (e.g., increased sensitivity to fosmidomycin after glycolytic enzyme mutation in Plasmodium[1][8])